Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 CAD | 0.00% | +0.12% | -7.70% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
Sales 2024 * | 35M 25.58M | Sales 2025 * | 38.7M 28.29M | Capitalization | 98.76M 72.19M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 2.82 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
15.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.46% |
Latest transcript on BioSyent Inc.
1 week | +0.12% | ||
Current month | -2.18% | ||
1 month | -2.07% | ||
3 months | -0.58% | ||
6 months | +8.13% | ||
Current year | -7.70% |
Managers | Title | Age | Since |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 8.51 | 0.00% | 3,825 |
24-04-25 | 8.51 | +1.31% | 7,093 |
24-04-24 | 8.4 | 0.00% | 65,245 |
24-04-23 | 8.4 | 0.00% | 2,777 |
24-04-22 | 8.4 | -1.18% | 3,736 |
Delayed Quote Toronto S.E., April 26, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.70% | 72.15M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- RX Stock